Varicella Virus Vaccine Live: A 22-Year Review of Postmarketing Safety Data

Meredith Woodward, Ann Marko, Susan Galea, Barry Eagel, and Walter Straus

Merck & Co., Inc., Kenilworth, New Jersey

Background. Varicella, a contagious infectious disease caused by varicella zoster virus (VZV), can result in hospitalization and, occasionally, death. Varicella virus vaccine live (VVVL [VARIVAX]) was introduced in the United States in 1995.

Methods. This comprehensive review of the VVVL safety profile is based on 22 years of postmarketing adverse event (AE) data received through spontaneous and noninterventional study reports submitted by health care providers and on a review of the published literature (cumulatively from March 17, 1995, through March 16, 2017, during which period >212 million doses were distributed globally).

Results. The VVVL safety profile was consistent with previous publications, with common AEs including varicella, rash, and pyrexia. AE reports have decreased over time, from ~500 per million doses in 1995 to ~40 per million doses in 2016; serious AEs comprise 0.8 reports per million doses. Secondary transmission was rare (8 confirmed cases); polymerase chain reaction analysis indicated that 38 of the 66 reported potential secondary transmission cases of varicella were attributable to wild-type VZV. The prevalence of major birth defects in the Pregnancy Registry was similar to that in the general US population. In total, 86 cases of death were reported after vaccination with VVVL; immunocompromised individuals appeared to be most at risk for a fatal varicella- or herpes zoster–related outcome.

Conclusions. This comprehensive 22-year review confirms the overall safety profile for VVVL, with no new safety concerns identified. Since VVVL’s introduction in 1995, notable declines in varicella cases and in varicella-related deaths have occurred compared with the prevaccination period.

Keywords. postmarketing; safety; varicella; varicella vaccine; varicella zoster vaccine.
reports from health care providers and consumers. Although ideally all AEs should be reported, this is a voluntary process, with the level of detail dependent upon the individual who submits the report. Despite efforts to solicit additional facts, demographic, medical/clinical, and laboratory information may vary in completeness and accuracy. The database also includes AEs from noninterventional studies and the published literature. The National Childhood Vaccine Injury Act of 1986 [10] requires that certain AEs occurring postvaccination in the United States be reported to the Vaccine Adverse Event Reporting System.

Once received by MSD, AEs are coded using preferred terms from the Medical Dictionary for Regulatory Activities (MedDRA) [11].

This analysis includes all spontaneous postmarketing and noninterventional study reports submitted by health care providers or reported in the published literature received worldwide during the 22-year period following licensure of VVVL, from March 17, 1995, through March 16, 2017 (reports received from consumers present in the database were not included in this analysis). The available data are inadequate to reliably estimate the number of exposed individuals; therefore, reporting rates are calculated based on total doses distributed, with the assumption that each patient received 1 dose. Time to AE onset was calculated from the date of vaccination (day 1) to the date of onset of the first reported AE. AE outcome was defined as the outcome provided at the time of the report. Reports of rash (including HZ, HZ-like, varicella, and varicella-like rash) were evaluated between 1 and 42 days postvaccination. The 42-day time frame, based on twice the VZV incubation period of 21 days, represents the upper limit of time during which a vaccinee would be expected to mount an immune response.
MSD Pregnancy Registry

VVVL is contraindicated during pregnancy. The company recommends that women avoid pregnancy for 3 months after vaccination; however, the Advisory Committee on Immunization Practices (ACIP) recommendation for live varicella vaccine administration advises that pregnancy be avoided for 1 month following each dose of VVVL [2]. However, it is recognized that, despite these contraindications and precautions [7], vaccination of pregnant women may occur inadvertently. A Pregnancy Registry was established (March 1995) to collect reports of and evaluate the safety and outcomes of women reported to have received VVVL within 3 months before conception or during pregnancy. On October 16, 2013, the Registry was closed to new enrollment [12]; individuals enrolled before closure were followed until after their estimated delivery date.

Definitions

The MedDRA preferred terms are listed in Supplementary Appendix 1. A report may contain ≥1 AE and includes all AEs reported by that individual. Serious AEs (SAEs) were defined per the International Conference on Harmonisation guidelines [13, 14]. Secondary transmission was defined as the documented presence of Oka/Merck vaccine strain VZV in a nonvaccinated contact of an individual vaccinated with VVVL. Based on European Medicines Agency (EMA) guidelines [15], potentially immunocompromised patients were identified based on medical histories, concurrent conditions, and concomitant therapies. Samples were analyzed using polymerase chain reaction (PCR) methodology to confirm the presence and type (vaccine strain or wild-type virus [WTV]) of VZV [16].

RESULTS

Postmarketing Surveillance Data: Overview

During the 22-year evaluation period, >212 million doses of VVVL were distributed worldwide, and 46,855 AE reports were received. Rates of the most commonly reported AEs are presented in Figure 2. From 1995 to 2000, the most common AE was varicella (peaking at 183 reports per 10^6 doses in 1997). In 2006, reports of varicella trended upward again, with 170 reports per 10^6 doses, but have subsequently decreased, with 4–5 reports per 10^6 doses in 2015 and 2016. Reports of rash also decreased, from 165 per 10^6 in 1995 to 10 per 10^6 in 2016.

Rates of SAEs fluctuated over time (Figure 3). Central nervous system (CNS) SAEs declined by approximately two-thirds during the review period, whereas the incidence of varicella SAEs remained relatively stable during that time.

Reports of AEs of interest, with PCR analysis from all laboratories, are presented in Table 1. Table 2 presents AEs reported in immunocompromised patients in whom vaccine strain VZV was identified.

Varicella After Vaccination

There were 10,677 reports of 11,095 varicella events (10,751 AEs, 344 SAEs). Time to onset was available for 6,692 reports, of which 22% (1,471/6,692) occurred within 42 days postvaccination. Of the 56% (5,927/10,677) of cases with

![Figure 2.](#) VVL global adverse event (AE) reports for the most common AEs, March 1995 to March 2017. Reported as AEs per 1 million doses distributed. See Supplementary Appendix 1 for a full breakdown of MedDRA preferred terms. Includes January 1, 2017, to March 16, 2017. Abbreviation: VVL, varicella virus vaccine live [VARIVAX [Oka/Merck]; Merck & Co., Inc., Kenilworth, NJ, USA].

Varicella Vaccine 22-Year Safety Review • OFID • 3
a reported outcome, 93% (5519/5927) were recovered/recovering and 7% (403/5927) had not recovered at the time of reporting; 9 cases resulted in a fatal outcome (Supplementary Appendix 2). Most fatal outcomes occurred in immunocompromised patients, in whom VVVL is contraindicated (see below). Lesion samples (n = 204; more than 1 sample may have been submitted per patient) submitted for PCR testing included 49 from immunocompromised patients (32 vaccine strain VZV, 9 WTV, 4 untypable/no strain identified, and 4 inadequate samples).

**Herpes Zoster**
Over the evaluation period, 1602 reports of 1803 HZ events were submitted (1646 AEs, 157 SAEs). Of the 1602 reports with

### Table 1. PCR Results From All Laboratories by AE of Interest

| AE, b | Oka/Merck Vaccine Strain VZV | Wild-Type VZV | VZV-Negative | VZV-Positive Untypable/No Strainc | Inadequate Sample | Total |
|-------|-------------------------------|---------------|--------------|---------------------------------|-------------------|-------|
| Varicella | 67                              | 97             | 12            | 9                               | 19                | 204   |
| Herpes zoster | 117                              | 57             | 27            | 9                               | 51                | 261   |
| Rash events | 25                              | 39             | 33            | 4                               | 27                | 128   |
| Secondary transmissiond | 8                               | 38             | 14            | 0                               | 8                 | 68    |
| CNS eventsf | 17f                              | 7              | 40            | 11                              | 3                 | 78    |
| Other AEsg | 17                              | 2              | 13            | 5                               | 2                 | 39    |
| Total No. of samples | 251                              | 240            | 139           | 37                              | 110               | 778   |

Abbreviations: AE, adverse event; CNS, central nervous system; CSF, cerebrospinal fluid; PCR, polymerase chain reaction; VZV, varicella zoster virus.

aIncludes January 1, 2017, to March 16, 2017. Abbreviations: CNS, central nervous system; SAE, serious adverse event; VVVL, varicella virus vaccine live (VARIVAX [Oka/Merck]; Merck & Co., Inc., Kenilworth, NJ).

Figure 3. VVVL global SAE reports for the most common SAEs, March 1995 to March 2017. Reported as SAEs per 1 million doses distributed. See Supplementary Appendix 1 for a full breakdown of MedDRA preferred terms. aIncludes January 1, 2017, to March 16, 2017. Abbreviations: CNS, central nervous system; SAE, serious adverse event; VVVL, varicella virus vaccine live (VARIVAX [Oka/Merck]; Merck & Co., Inc., Kenilworth, NJ).
| Age, Sex | Reported AE(s) | TTO PV for Vaccination-Associated AE | Medically Significant Case Information | IS Concomitant Therapies | PCR Analysis for VZV | AE Recovery Status at Time of Report |
|---|---|---|---|---|---|---|
| 12 mo, male | Disseminated varicella (as reported) | NR | “Severe immuno deficiency” | NR | Oka/Merck vaccine strain VZV identified in lesion sample | NR |
| 13 mo, male | Pulmonary hemorrhage; Cardiac failure congestive; Hematemesis; Hypoglycemia; Lethargy; Retching; Respiratory distress; Pneumonitis; Rash papular; Hemolytic anemia; Rash vesicular; Candida pneumonia; Hepatomegaly; Varicella zoster virus infection; Lung disorder; Lymphadenopathy | 27 d | DiGeorge’s syndrome (central shunt); Cardiac failure; Congestive and complex congenital heart disease; History of Fallot’s tetralogy; Rastelli repair; Oral candidiasis recurrent; Immunosuppression; Concomitant vaccination with MRV on same day, CDC reported that the tracheal aspirate was positive for measles virus | None | Oka/Merck vaccine strain VZV identified in bronchial washings and lesion samples | Varicella cleared; Patient subsequently died of pulmonary hemorrhage after prolonged intubation for chronic lung disease |
| 13 mo, male | Subacute sclerosing panencephalitis; Immunodeficiency; Varicella; Diarrhea; Malnutrition; Hypogammaglobulinemia; Leukopenia; Vasculitis cerebral | 21 d | Primary immune deficiency; Clinically defective antiviral T-cell function | None | Oka/Merck vaccine strain VZV identified in lesion samples | Varicella cleared; Patient subsequently died of measles inclusion body encephalitis |
| 13 mo, male | Pneumonia viral; Vomiting; Croup infectious; Varicella; Dermatitis bullosus; Lumbar radiculopathy; Antibody test negative | 14 d | History of failure to thrive and oral candidiasis; Subsequently diagnosed with HIV | None | Oka/Merck vaccine strain VZV identified in BAL and lung biopsy material | Recovered; No recurrence of varicella |
| 13 mo, male | Combined immunodeficiency; Drug administration error; Diarrhea; Pyrexia; Pneumonia; Hepatitis; Malaise; Enterovirus infection; Hepatic function abnormal; Ascites; Hepatomegaly; Leukocytosis; Respiratory distress; Nasopharyngitis; Necrosis; Influenza; Coagulopathy; Collitis; Feeling abnormal; Dehydration; Amebiasis; Varicella; Neutropenia; Lymphopenia; Viral infection; Bronchitis | 15 d | PV hospital-ized and 28 d varicella rash | Adenosine deaminase deficiency; Bronchiolitis; Reactive airway disease; Recurrent oral candidiasis | None | Oka/Merck vaccine strain VZV identified from liver biopsy and lesion sample | Recovered |
| 13 mo, female | Hemorrhage intracranial; Combined immunodeficiency; Mumps; Lung disorder; Leukopenia; Drug tolerance; Hepatitis; Disseminated intravascular coagulation; Hemolytic, Pseudomonas infection; Rubella; Adenovirus infection; Renal failure; Acidosis; Hyperammonemia; Pancreatitis; Amylase increased; Carbon dioxide increased; Acute respiratory distress syndrome; Measles; Respiratory failure; Cough; Diarrhea; Rash vesicular; Varicella; Pyrexia | 25 d | Adenosine deaminase deficiency; History of recurrent sinopulmonary infections; Refractory oral candidiasis; Poor weight gain | Inhaled corticosteroid | Oka/Merck vaccine strain VZV identified in BAL and lesion samples; Samples also noted to be positive for measles, mumps, and rubella vaccine strains | Varicella cleared; Patient subsequently died of intracranial hemorrhage while on ECMO |
| 13 mo, female | Autoimmune hemolytic anemia; Renal failure; Hepatic failure; Disseminated intravascular coagulation; Disseminated varicella zoster virus infection; Lymphopenia; Mumps; Rubivirus test positive | 21 d | Primary immunodeficiency due to heterozygous missense mutation in recombination activating gene 2 diagnosed PV | None | Oka/Merck vaccine strain VZV identified in CSF, skin, and esophagus; VZV was identified in autopsy tissues in lungs and liver; Corneal dendrites with typical features of VZV | Patient died due to multi-organ failure associated with disseminated varicella |
| 13 mo, female | Herpes zoster disseminated; Herpes zoster | 35 d to disseminated HZ occurrence; 61 d to possible recurrent episode of HZ | Congenital dyskeratosis | NR | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered from first workup; Not recovered from the “possible” recurrence of HZ at the time of the report |
| 13 mo, female | Meningoencephalitis viral; Varicella zoster; Rubella viral infection | 3 wk | Severe combined immune deficiency; Neutropenia | Myeloblastation and hematopoietic stem cell transplantation | Oka/Merck vaccine strain VZV identified in serum, lesion, urine, nasopharyngeal swab, and oropharyngeal swab, and VZV (untyped) identified in the CSF | Recovered |
| 14 mo, male | Aspartate aminotransferase increased; Varicella; ALT increased; Febrile reaction; Cough; Upper respiratory tract congestion | 18 d | Asthma; “Serious immunodeficiency” not further specified | None | Oka/Merck vaccine strain VZV identified in lesion sample | Patient has progressive varicella with workup ongoing |
Table 2. Continued

| Age, Sex | Reported AE(s) | TTO PV for Vaccination-Associated AE | Medically Significant Case Information | IS Concomitant Therapies | PCR Analysis for VZV | AE Recovery Status at Time of Report |
|----------|----------------|--------------------------------------|---------------------------------------|--------------------------|----------------------|--------------------------------------|
| 15 mo, male | Renal function disorder; Herpes zoster; Hypertension; Pyrexia; Neutropenia; Encephalopathy | ~ 3 mo | Neuroblastoma; Bone marrow transplantation | Chemotherapy | Oka/Merck vaccine strain VZV identified in lesion and CSF samples | Recurrent episodes of HZ over several wk, but patient recovered and was discharged |
| 15 mo, female | Multi-organ failure; Respiratory distress; Sepsis; Varicella; Varicella Zoster pneumonia; Pneumothorax; Respiratory distress; Acute respiratory failure; Contraindication to vaccination | 20 d | Unconfirmed underlying immunodeficiency; Developmental delay; Failure to thrive; Muscular dystrophy; Hypotonia | Budesonide; Methyprednisolone; Prednisone | Oka/Merck vaccine strain VZV identified in lesion and BAL samples | Patient died of respiratory/multi-organ failure associated with disseminated varicella |
| 17 mo, female | Varicella zoster virus infection | >4 mo | Immunodeficiency; Hurler syndrome; HLA matched cord blood transplant | None | Oka/Merck vaccine strain VZV identified in lesion sample | Lesions crusted over |
| 17 mo, female | Varicella zoster virus infection | 16 d | Failure to thrive; Abnormal IgG levels (unknown at time of vaccination); T lymphocyte count abnormal; Intestinal dysmotility | NR | Oka/Merck vaccine strain VZV identified in lesion sample | NR |
| 17 mo, female | Varicella zoster virus infection; Anemia macrocytic; Pancytopenia; Lymphopenopathy; Rash vesicular; Aplastic anemia | 23 d | Macrocytosis-normal chromic-hyporegenerative anemia | NR | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 18 mo, male | Herpes zoster (reported as mild); asthma | 122 d | Asthma exacerbation requiring corticosteroid use | Corticosteroid | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 18 mo, female | Respiratory failure; Varicella; Staphylococcus aureus bacteremia; Systemic candida; Methicillin-resistant S. aureus infection | 4 wk | Deficits in cellular immunity; Severe humoral dysregulation | None | Oka/Merck vaccine strain VZV identified in lesion sample | Variella cleared; Patient subsequently died of respiratory failure at 2 y 2 mo of age |
| 20 mo, male | Herpes zoster | 214 d | S/p “recent” liver transplant | Tacrolimus | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 21 mo, female | Neuroblastoma recurrent; Respiratory arrest; Acute renal injury; Mentally late developer; Leukocytosis; Proteinuria; Varicella; Meningitis | 35 d | Stage IV neuroblastoma diagnosed 1 wk PV | Chemotherapy (4 courses of cyclophosphamide, adriamycin, and vincristine, and 2 courses of cisplatin and etoposide), followed by autologous stem cell transplant | Oka/Merck vaccine strain VZV identified in lesion sample | Variella cleared; Patient subsequently died of complications of neuroblastoma |
| 22 mo, female | Herpes zoster; Immunoglobulins increased; Cellulitis; Otorrhea | 10 mo | Diagnosed with Job-Buckley syndrome after vaccination (date not reported) | NR | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 2 y, male | Skin lesion; Leukemia | 37 d | Diagnosed with leukemia after vaccination | NR | Oka/Merck vaccine strain VZV identified in lesion sample | Recovering |
| 25 mo, male | Acute lymphocytic leukemia; Herpes zoster | 22 d | Diagnosed with acute lymphocytic leukemia 10 d PV | Chemotherapy | Oka/Merck vaccine strain VZV identified in lesion sample | 3 episodes of HZ over several wk, but ultimately recovered |
| 25 mo, male | Herpes zoster; Asthenia; Decreased appetite; Pain in extremity; Somnolence; Astrocycytoma | 8 mo | Dienecephalic syndrome, “suboptimal” growth, developmental delays | Started on chemotherapy for newly diagnosed astrocytoma 2 mo before developing HZ (carboplatin and vincristine) | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered from HZ event |
| 3 y, male | Varicella; Hepatic function abnormal | 19 d | History of severe combined immunodeficiency, s/p unrelated bone marrow transplantation | NR | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 4 y, NR | Herpes zoster; Meningitis; Acute lymphocytic leukemia | 19 mo | Diagnosed with acute lymphocytic leukemia >1y PV | Chemotherapy | Oka/Merck vaccine strain VZV identified from CSF and lesion sample | Recovered |
| 4 y, female | Herpes zoster | 21 mo | Dermatomyositis | Prednisone; Methotrexate | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 5 y, female | Varicella; Medication error; Pneumonia; Pyrexia; HIV test positive | 36 d | HIV-positive | Antiviral (unspecified); Lopinavir + ritonavir | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 5 y, male | Herpes zoster | 453 d | Neutropenia | None | Oka/Merck vaccine strain VZV identified in lesion sample | Recovering |
| Age, Sex | Reported AE(s) | Medically Significant Case Information | IS Concomitant Therapies | PCR Analysis for VZV | AE Recovery Status at Time of Report |
|----------|----------------|----------------------------------------|--------------------------|---------------------|-----------------------------------|
| 5 y, male | Varicella; Neutropenia, Product use issue | NR | Immunocompromised (not further specified) | NR | Oka/Merck vaccine strain VZV identified in lesion sample | NR |
| 5 y, male | Pneumonia; Rash | 10 d | Reactive airway disease; Cerebral palsy | Steroids (1–2 mg/kg/d prednisolone sodium phosphate) | Oka/Merck vaccine strain VZV identified in endotracheal secretions | Recovered |
| 5 y, male | Herpes zoster; Lung infection; Chronic granulomatous disease | 11 mo | X-linked chronic granulomatous disease; Chronic renal failure; Hypertension; Chronic diarrhea | Cord blood transplant; Long-term prednisolone (1 mg/d) | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 5 y, female | Histiocytosis hematophagic; Pancytopenia; Hepatitis; Varicella zoster virus infection; Rash vesicular | 14 d after second dose | Immunodeficiency | Corticosteroids | Oka/Merck vaccine strain VZV identified in lesion sample | Resolving |
| 6 y, male | Varicella; varicella zoster pneumonia | 23 d | Cerebral palsy; Spastic quadriplegia; Seizures, recurrent otitis media; Selective reduction of iNKT cells combined with deficient expression of CD1d; Possible subclinical functional impairment of conventional T cells | NR | Oka/Merck vaccine strain VZV identified in lesion sample | NR |
| 6 y, female | Varicella | 17 d | Rheumatoid arthritis | Prednisone; Methotrexate | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 8 y, female | Rash vesicular; Rash popular; Pyrexia; Localized infection | 23 d | Perinatally infected with HIV | None | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 9 y, male | Varicella; Accidental exposure to product; Molluscum contagiosum; Staphylococcal infection | 18 d | Split renal transplant secondary to end-stage renal disease | Mycophenolate mofetil; Tacrolimus; Prednisone | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 9 y, male | Varicella; Blood creatinine increased; Nephrotic syndrome | 20 d | Systemic lupus erythematosus | Pulse steroids | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 11 y, male | Varicella; Headache; Meningitis; Mycobacterium avium complex infection; Depression; Malnutrition; Protein-losing gastroenteropathy; Cytomegalovirus viremia; Pyrexia; AIDS-related complications; Ear infection | ~1 y from second dose, fifth episode of recurrent varicella | Congenital AIDS | None | Oka/Merck vaccine strain VZV identified in lesion sample | Patient with 5 episodes of recurrent varicella. The patient recovered from varicella; Death occurred approximately 1 y 3 mo postvaccination from AIDS complications |
| 11 y, female | Pneumonitis; Dermatitis bullous; Cystic fibrosis; Cell-mediated immune deficiency; Embolism | 5 wk | Congenital CMV; Recurrent respiratory infections; Immune deficiency; Cystic fibrosis | None | Oka/Merck vaccine strain VZV identified in BAL and endotracheal secretion sample | Recovered and discharged; patient died 10 mo PV due to embolic complications related to a femur fracture |
| 12 y, male | Renal transplant; Varicella; ANCA; Vasculitis; AST increased; ALT increased; Medication error; Drug administration error; Inappropriate schedule of drug administration | 28 d from second dose | Renal transplant; Trisomy 21 | Mycophenolate; Tacrolimus | Oka/Merck vaccine strain VZV identified in lesion sample | Resolving |
| 12 y, female | Varicella zoster virus infection; Gait instability; Back pain; Pain in extremity; Arthralgia | ~1 wk | Acute myeloid leukemia; Chronic graft-vs-host disease; 5-FU bone marrow transplant | Betamethasone | Oka/Merck vaccine strain VZV identified in lesion sample | NR |
| 14 y, male | Bone marrow transplant; Meningitis; Disseminated varicella zoster vaccine virus infection; Cord blood transplant therapy; Medication error | >10 y | Precursor B-cell acute lymphoblastic leukemia; Bone marrow transplant; Cord blood stem cell transplant; Graft-vs-host disease | Sirolimus; Tacrolimus; Budesonide | Oka/Merck vaccine strain VZV identified in CSF | Recovering |
| 15 y, female | Death; Dermatitis acralis form; Neurological symptoms; CD4 lymphocytes decreased; Medication error; Progressive multifocal leukoencephalopathy; Cerebellar syndrome; CNS lymphoma; CNS lesion | NR | Congenital HIV; Progressive multifocal leukoencephalopathy; HIV cerebellar syndrome; Possible CNS lymphoma | None | Oka/Merck vaccine strain VZV identified in CSF | Patient died of complications associated with HIV |
| Age, Sex | Reported AEs* | TTO PV for Vaccination-Associated AE | Medically Significant Case Information | IS Concomitant Therapies | PCR Analysis for VZV | AE Recovery Status at Time of Report |
|----------|---------------|--------------------------------------|---------------------------------------|-------------------------|----------------------|-----------------------------------|
| 19 y, male | Pneumothorax; Bilateral pneumonia; Rash generalized; Medication error; Varicella; Intubation; Mechanical ventilation; Back pain; Dialysis; Renal impairment; Tracheostomy; Malaise; Adverse drug reaction | 3 wk | Transplant; Allergies; History of IgA nephropathy; Immunosuppression | Prednisone; Mycophenolate mofetil | Oka/Merck vaccine strain VZV identified in lesion and saliva samples | Patient slowly stabilizing but remained hospitalized in the ICU |
| 19 y, male | Varicella; Pyrexia; Decreased appetite; Asthenia; Myalgia; Cough | ~22 d | Chronic hepatitis; Lymphopenia; ”Immune system disorder”; Primary sclerosing cholangitis | NR | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 20 y, male | Necrotising retinitis | ~1 wk | Inflammatory bowel disease; Protein-losing enteropathy; Hypogammaglobulinemia; Glucose-6-phosphate dehydrogenase deficiency | Multiple IS therapy | Oka/Merck vaccine strain VZV identified in vitreous aspirate | Lost to follow-up |
| 23 y, male | Varicella | 1 mo | HIV | None | Oka/Merck vaccine strain VZV identified in serum sample | Recovered |
| 30 y, female | Necrotising herpetic retinopathy; Varicella | 80 d | HIV | None | Oka/Merck vaccine strain VZV identified in ocular fluid | Lesions cleared; Patient discharged from hospital |
| 36 y, male | Varicella; Creatinine high | 24 d | Heart transplant 2 y before vaccination | Mycophenolate mofetil; Cyclosporine | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 45 y, female | Respiratory failure; Cholecystitis; Herpes zoster; Infection; Encephalitis; Pneumonia; Medication error | 1 mo | End-stage renal disease; Lupus; Failing renal transplant | IS therapy | Oka/Merck vaccine strain VZV identified in lesion sample | Patient died of unspecified infection |
| 48 y, male | Pneumonitis; Varicella; Death; Ascites | 19 d | Down syndrome; Drug hypersensitivity; History of dermatitis | None | Oka/Merck vaccine strain VZV identified in lesion and saliva samples | Recovered and discharged; Patient died 6.5 mo PV from pneumonia and ascites, not thought to be related to varicella vaccination |
| 54 y, male | Varicella; Seizure; Confusional state; Medication error; Inappropriate schedule of drug administration; Blood creatinine increased; Platelet count decreased | 14 d | Myelofibrosis; Rheumatoid arthritis; Epilepsy | Methotrexate; Ruxolitinib phosphate | Oka/Merck vaccine strain VZV identified in lesion sample | Recovered |
| 67 y, male | Pancytopenia; Herpes zoster; Hematitis; Bone marrow granuloma; Respiratory distress; Asthenia; Multi-organ dysfunction syndrome; Histiocytosis hematophagocytic; Varicella; Sebornoecrosis; Granuloma; Pneumonia; Bacteremia; Herpes zoster disseminated; Leukopenia; Neutropenia; Herpes zoster; Medication error | ~8 wk | Non-Hodgkin lymphoma; Chronic leukopenia; Prior chemotherapy and bone marrow transplantation | None | Oka/Merck vaccine strain VZV identified in lesion sample | Recurrent varicella lesions and shingles; Patient died of disseminated varicella (multi-organ failure) 7 mo PV |

**NR** male | Blindness; Necrotizing herpetic retinopathy | NR | Common variable immunodeficiency | NR | Oka/Merck vaccine strain VZV identified in aqueous fluid | Unknown |

| Unk/Unk | Varicella; herpes zoster | ~30 d (Varicella); 49 d to herpes zoster | History of leukemia | NR | Oka/Merck vaccine strain VZV identified in lesion sample | NR |

Abbreviations: AE, adverse event; ALT, alanine transaminase; ANCA, antineutrophil cytoplasmic antibody; AST, aspartate transaminase; BAL, bronchoalveolar lavage; CDC, Centers for Disease Control and Prevention; CMV, cytomegalovirus; CNS, central nervous system; CSF, cerebrospinal fluid; ECMO, extracorporeal membrane oxygenation; HZ, herpes zoster; IgA, immunoglobulin A; IS, immunosuppressive; MMR, measles, mumps, and rubella vaccine; MSD, Merck Sharp & Dohme; NR, not reported; PCR, polymerase chain reaction; PV, postvaccination; NR, not reported; s/p, status post; TTD, time to onset; Unk, unknown; VZV, varicella zoster virus.

*See Supplementary Appendix 1 for a full breakdown of MedDRA preferred terms.

an HZ event, 1342 reports included information about patient age (median age, 4 years; range, 11 months to 84 years). Time to onset was provided in 51% (817/1602) of reports, with 9% (71/817) occurring within 14 days postvaccination and 16% (134/817) occurring within 42 days postvaccination. Of the 63% (1008/1602) of cases with a reported outcome, 91% (914/1008) recovered, whereas 2 reports listed HZ as a cause of death (Supplementary Appendix 2). There were 260 reports with 261 rash/lesion samples submitted for PCR analysis, including 26 from immunocompromised patients (17 vaccine strain VZV, 4 WTV, 2 VZV-negative, 1 untypable/no strain identified, and 2 inadequate samples).
Rash (Nonvaricella, Non-HZ)

There were 6153 reports (6887 AEs, 345 SAEs) of a rash-related AE. Of the 4668 cases of rash with a reported time to onset (range, 1–5291 days), 76% (3527/4668) occurred within 42 days postvaccination (median, 9 days). An outcome was reported in 68% of cases (4078/6153), 90% (3678/4078) of which were recovered/recovering and 10% (410/4078) had not recovered (each case could include more than 1 rash event and, therefore, more than 1 event outcome). No fatal outcomes were reported. There were 127 reports with 128 rash/lesion samples submitted for PCR analysis, including 4 from immunocompromised patients (2 vaccine strain VZV, 1 WTV, and 1 inadequate sample).

Secondary Transmission

During the review period, 357 reports containing the AE “secondary transmission” were received. Outcome was reported in 91 of 357 cases (25%), of which 84 (92%) recovered, 6 (7%) did not recover, and 1 (1%) died (Supplementary Appendix 2). PCR analysis was performed in 66 cases (with 68 samples), including 6 immunocompromised patients (5 WTV and 1 inadequate sample).

CNS Events

There were 781 reports that included CNS events, the majority of which were febrile convulsion (35%), seizure (32%), ataxia (8%), and encephalitis (7%) (Supplementary Table 1). SAEs comprised 73% (571/781) of CNS event reports. The mean time to onset was 57 days postvaccination (median [range], 9 [1–3886] days). Seventy-three cases with 78 samples (samples for PCR analysis included cerebrospinal fluid and brain tissue) submitted for PCR analysis were reported, including 9 from immunocompromised patients (7 vaccine strain VZV, 1 VZV negative, and 1 untypable/no strain identified).

Disseminated Vaccine-Strain VZV

Disseminated disease caused by the Oka/Merck vaccine strain VZV, with or without visceral involvement, was confirmed by PCR analysis in 39 cases. Eleven cases occurred in immunocompetent individuals, and 28 involved patients who had underlying immunosuppressive conditions and/or who reported concomitant use of immunosuppressant therapies (Tables 2 and 3). Among the 11 immunocompetent patients, vaccine strain VZV was identified in cerebrospinal fluid (CSF; n = 10), lesion samples (n = 2), gastric mucosa (n = 1), and saliva (n = 1); among the 28 immunocompromised patients, vaccine strain VZV was identified in lesion samples (n = 18), bronchoalveolar/sputum (n = 8), CSF (n = 6), ocular samples (n = 3), other samples (n = 3), lung biopsy (n = 1), liver biopsy (n = 1), and serum (n = 1).

Pregnancy

All Pregnancy Cases Reported to MSD

Between March 17, 1995, and March 16, 2017, 1216 women were exposed to VVVL during pregnancy and had pregnancy outcomes available for analysis (Table 4). Timing of exposure was available in 1066/1216 reports, including 883 pregnancies that resulted in 895 liveborn infants (1 set of triplets, 10 sets of twins). Of the 883 reports of live births with known timing of exposure, 288 (32.6%) women received VVVL vaccination before their last menstrual period (LMP), 511 (57.8%) were vaccinated in the first trimester and 84 (9.1%) were vaccinated after the first trimester. Of the women exposed to VVVL before or during pregnancy, congenital anomalies were noted in 56 reports (congenital anomalies include major birth defects as defined by the Metropolitan Atlanta Congenital Defects Program [MACDP]—a population-based tracking system for birth defects among children and infants born to mothers living in metropolitan Atlanta—and congenital anomalies that do not meet MACDP classification as major anomalies), with 14 women exposed before their LMP, 33 exposed in the first trimester, and 9 with unknown time of exposure. Utilizing ACIP recommendations to avoid pregnancy for 1 month after vaccination, 180 of the 288 women were vaccinated <30 days before LMP. Of the 14 reports of congenital anomalies in women exposed before LMP, 6 were vaccinated <30 days before LMP.

MSD Pregnancy Registry

Among the 1522 prospectively enrolled women, there were 966 pregnancy outcomes with 809 live births (819 total infants), none of whom had features consistent with congenital varicella syndrome. Twenty-two reports of major birth defects were submitted. Using the MACDP methodology [17], including pregnancies that progressed >20 weeks post-LMP, 17 defects occurred among 819 live births, giving a birth prevalence of 2.1 per 100 liveborn infants (95% confidence interval [CI], 1.2–3.3) [1]. Pregnancy outcomes in these 17 women included 16 live births and 1 elective termination at 32 weeks’ gestation. The MACDP methodology was revised to include elective terminations after prenatal diagnoses of birth defects at any gestational age (minimum and maximum adjusted defect prevalences were calculated by adding definite prenatal defects and definite plus possible prenatal defects to the hospital-based cases) [18], which allowed 4 elective terminations at <20 weeks’ gestation with a diagnosis of a fetal abnormality to meet the inclusion criteria; the resulting 21 major defects provided a birth defect prevalence of 2.6 per 100 liveborn infants (95% CI, 1.6–3.9). In the general US population, approximately 3% of all births (live births or stillbirths) are diagnosed with major birth defects [19]. Using either methodology, the prevalence of major birth defects in the Registry is similar to that in the general population.
Fatal outcomes temporally, but not necessarily causally, associated with VVVL were reported in 86 of 46,855 (0.002%) postmarketing reports, including 26 from immunocompromised patients (Figure 4). Twenty-one reports (24%) provided insufficient information for further discussion. Of the remaining 65 cases (24 in immunocompromised individuals), death was associated with the following: preexisting conditions (n = 17), complications of varicella (n = 11), complications of herpes zoster (n = 2), other infections (n = 9), pulmonary

### Table 3. Summary of Cases of Disseminated Disease With Confirmed Oka/Merck VZV in Immunocompetent Patients

| Age, Sex | Reported AEs | TTO PV for Vaccination-Associated AE | Reported Health Status | Concomitant Therapies | PCR Analysis for VZV | AE Recovery Status at Time of Report |
|----------|--------------|--------------------------------------|------------------------|-----------------------|----------------------|-------------------------------------|
| 3 y, female | Encephalitis; Vomiting; Ophthalmic herpes zoster; Meningitis | 1.6 y | No history of severe or frequent infections; Considered by physician to have been immunocompetent | | Oka/Merck vaccine strain VZV identified in CSF | Recovered |
| 4 y, male | Meningitis aseptic; Herpes zoster; Pain in extremity | 2.6 y | No history of disease or immunosuppressive illness | | Oka/Merck vaccine strain VZV identified in CSF | NR |
| 7 y, male | Meningitis; Herpes zoster | 6 y | Previously healthy | | Oka/Merck vaccine strain VZV identified in CSF and skin lesion | Recovered |
| 8 y, male | Herpes zoster; Meningitis | 7 y | No significant medical history; No prior atypical infections or recognized exposure to varicella; Received 1 dose of varicella vaccine at age 1 y | | Oka/Merck vaccine strain VZV identified in CSF and lesion sample | Recovered |
| 8 y, male | Meningitis; Herpes zoster | 3.2 y | Normal healthy child; Negative HIV test | Vaccinated against hepatitis A, MMR, hemophilus B, diphtheria, pertussis, tetanus, polio, pneumococcus, influenza | Oka/Merck vaccine strain VZV identified in CSF | Recovered |
| 9 y, male | Meningitis aseptic; Herpes zoster | 8 y | Previously healthy; No history of fever or vomiting; No history of recent contact with anyone with a rash or varicella-like illness; Received 1 dose of VVVL at age 1 y; Never had a chickenpox-like illness | | Oka/Merck vaccine strain VZV identified in CSF | Recovered |
| 12 y, female | Meningitis; Herpes zoster | 11 y | Previously healthy | | Oka/Merck vaccine strain VZV identified in CSF | NR |
| 11 y, male | Varicella virus test-positive; Meningitis aseptic | 6.5 y from second dose | Immunocompetent; No chickenpox exposure; No history of breakthrough disease; No shingles or rash | | Oka/Merck vaccine strain VZV identified in CSF | Recovered |
| 13 y, male | Rash vesicular; Herpes zoster meningoencephalitis; Lid lag; Enterovirus test-positive | –8 y from second dose | Healthy patient; No chronic conditions, acute infections, or immunosuppressive medications | | Oka/Merck vaccine strain VZV identified in CSF | Recovered |
| 16 y, male | Gastric perforation; Gastritis; Hemorrhage; Inappropriate schedule of drug administration; Gastric ulcer | – 3 y from second dose | Family history of a sibling who died after gastric perforation; Possible inherited immune condition conferring susceptibility to acquiring infection; Additional tests to evaluate immune cell function unsuccessful owing to patient noncompliance | Albuterol; Montelukast sodium | Oka/Merck vaccine strain VZV identified in gastric mucosa from endoscopy biopsy | Recovered |
| NR, “child” Herpes zoster; Headache; Photophobia; Vomiting | –4 y | Normal host; No known immunosuppression | | | | |

Abbreviations: AE, adverse event; CSF, cerebrospinal fluid; MMR, measles, mumps, and rubella vaccine; NR, not reported; PCR, polymerase chain reaction; PV, postvaccination; NR, not reported; TTO, time to onset; VVVL, varicella virus vaccine live (VARIVAX [Oka/Merck]; Merck & Co., Inc., Kenilworth, NJ); VZV, varicella zoster virus.

*See Supplementary Appendix 1 for a full breakdown of MedDRA preferred terms.*
complications (n = 6), cardiac complications (n = 5), CNS (n = 4), and other causes (n = 11) (Supplementary Appendix 2).

DISCUSSION

Although clinical trials are necessary to determine vaccine safety, immunogenicity, and efficacy, postmarketing surveillance is an essential tool to monitor safety profiles postlicensure [20]. The strength of postmarketing surveillance is that it provides information on real-world use in larger populations than is possible with clinical trials, may include populations not included in clinical trials, and identifies less common and/or rare AEs that may not be observed during clinical trials [21]. These strengths are balanced by the limitations of postmarketing surveillance, which relies heavily on voluntary, passive reporting and is often incomplete. Additionally, the number of exposed (vaccinated) persons is an estimation only [22], and thus calculation of accurate AE incidence rates is limited. Evidence included in AE reports, which includes medical information and diagnostic and laboratory data, is provided by the individual who submits the report, generally without confirmation. The data available in AE reports can be sufficient to provide temporal associations but are generally inadequate to establish causality [23]. In this review, we summarize reports and outcomes collected over >2 decades of postmarketing surveillance of VVVL, with safety surveillance further enhanced by PCR analysis.

During 22 years of routine VVVL use, rates of many AEs and SAEs have noticeably decreased, particularly those of varicella and rash. Concerning reports of varicella, most cases occurred >42 days postvaccination, and PCR data suggest that most cases resulted from infection with WTV. However, reports of pyrexia and serious pyrexia appear to have rebounded in recent

### Table 4. Pregnancy Outcomes With VVVL

| Pregnancy Outcomes, No. (%) | Prospective | Retrospective |
|-----------------------------|-------------|---------------|
| All Reports Between March 17, 1995, and March 16, 2017 (n = 1216) |             |               |
| Reports                      | n = 1092    | n = 124       |
| Outcomes                     | n = 1102    | n = 127b      |
| Live birth                   | 917 (83.2)  | 83 (65.4)     |
| Spontaneous abortion         | 109 (9.9)   | 31 (24.4)     |
| Elective abortion            | 74 (6.7)    | 8 (6.3)       |
| Stillbirth/fetal death        | 1 (0.1)     | 5 (3.9)       |
| Ectopic pregnancy            | 1 (0.1)     | 0             |

Pregnancy outcomes comprise all reports worldwide, including reports from health care providers, consumers, and the Pregnancy Registry. Abbreviation: VVVL, varicella virus vaccine live (VARIVAX [Oka/Merck]; Merck & Co., Inc., Kenilworth, NJ).

\[a\]Includes 8 sets of twins and 1 set of triplets.

\[b\]Includes 3 sets of twins.

### Figure 4. Cases with fatal outcomes. \[a\]Full details are provided in Supplementary Appendix 2. Abbreviations: CNS, central nervous system; OTC, ornithine transcarbamylase; PCR, polymerase chain reaction; SIDS, sudden infant death syndrome; VZV, varicella zoster virus; WTV, wild-type virus.
years. This increase may be related to the implementation of programs—such as that undertaken in Italy between 2013 and 2014 [24], in which parents of a vaccinated child received preprinted diary cards for specific AEs (eg, injection site reactions, fever, convulsions, headache)—that have correlated with an increase in the reporting of vaccination-associated AEs [25]. Changes in coding also likely contributed to the increase in pyrexia reports. In 2016, MSD adopted the European Medicines Agency list of terms for important medical events [26]; because hyperpyrexia is included in the list, the incidence of pyrexia as an SAE increased almost 3-fold (to 6.14 per million doses between 2015 and 2017), although in the vast majority of reports, medical intervention was not required.

The shift from a 1-dose to a 2-dose vaccination regimen in 2006 was recommended to improve immunity levels, with the second dose added to improve humoral and cellular responses. The introduction of the second dose corresponds with a temporal decrease in the rate of varicella among children and adolescents and a 3.3-fold lower risk of breakthrough disease compared with the prevaccination era [4, 7, 27]. Importantly, overall AE rates did not increase following the introduction of the 2-dose regimen, and no new commonly occurring AEs have been noted in the years since then.

It has been suggested that widespread vaccination may result in decreased maintenance of community immunity, leading to a shift in infections toward older individuals owing to VZV reactivation [2, 28, 29], but to date, studies examining rates of varicella and HZ in adults in the postvaccination era have reported conflicting results [2, 30]. A recent literature review of severe breakthrough cases resulting in disseminated VZV infection suggested that most cases occurred within 5 years of vaccination—that is, in children rather than in adults [31]. Our data would support this, as the immunocompetent patients in whom disseminated disease developed were children (aged 3–16 years) who developed symptoms 2–14 years after vaccination.

Although systemic postvaccination infections are rare in immunocompetent patients, we report 11 cases of Oka/Merck vaccine strain VZV in immunocompetent patients. Secondary transmission is also an uncommon event but has the potential to cause complications in a susceptible contact, such as an immunocompromised or pregnant individual. In prevaccination-era studies, the secondary infection rate of varicella among susceptible children ranged from 61% to 100% [32–34]. In the current analysis, 357 cases (0.0001% of >212 million doses) of potential secondary transmission were recorded, although 38/68 analyzed by PCR proved to be WTV. AEs during pregnancy were uncommon; the prevalence of major birth defects in the Pregnancy Registry was similar to that observed in the general population, and no new safety concerns among susceptible women exposed to the varicella vaccine were identified.

VZV is neurotropic, with recognized presentations including meningoencephalitis, hemiparesis, hemiplegia, myelitis, and peripheral neuritis [35, 36]; however, in general, neurologic complications reported after vaccination were rare. In this analysis, the most commonly reported CNS AEs were seizures/convulsions, which are noted as potential AEs in the VVVL prescribing information [7].

Overall, 86 deaths were reported after VVVL vaccination; however, almost 25% of reports contained insufficient data to identify the cause of death. Immunocompromised individuals are at the highest risk for a fatal varicella-related outcome, and it is important to reiterate that the potential risk of disseminated disease contraindicates VVVL (and other live viral vaccines) in immunosuppressed or immunodeficient individuals, including those on immunosuppressive therapy [7]. Overall, 13 deaths were associated with varicella or HZ, 12 of which occurred among immunocompromised patients. One varicella-associated fatality occurred in an immunocompetent patient and was confirmed by PCR as being due to WTV. Reports of HZ were uncommon (~1 report per 200,000 doses), and although most patients recovered, both cases of HZ with a fatal outcome involved immunocompromised individuals. Oka/Merck vaccine strain VZV was detected from specimens obtained from all 32 immunocompromised patients reporting disseminated disease after receiving VVVL, reinforcing the contraindication for vaccination in these individuals.

CONCLUSIONS
This 22-year analysis, the largest to date, presents the worldwide safety profile as based on spontaneous postmarketing reports for VVVL vaccine after distribution of >212 million doses of vaccine. In addition to VVVL’s proven efficacy profile, these data confirm that VVVL is safe and generally well tolerated. Results were consistent with safety trends reported in previous analyses [8, 37], and the overall safety profile of VVVL is consistent with findings from pivotal clinical trials. MSD continues to conduct routine postmarketing surveillance to identify any temporal associations between VVVL vaccine and AEs in order to inform public health practice and ensure the integrity of its product.

Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments
Medical writing and editorial assistance were provided by Sally Mitchell, PhD, of ApotheCom, Yardley, Pennsylvania. This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey.

Financial support. This work was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey.

Disclaimer. In conjunction with the external investigators, this research was designed, executed, and analyzed by the sponsor. Although the sponsor formally reviewed a penultimate draft of this manuscript, the
opinions expressed are those of the authors and may not necessarily reflect those of the sponsor.

Potential conflicts of interest. All authors are employees of Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, and hold stock in Merck & Co., Inc., Kenilworth, New Jersey. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Author contributions. M.W., A.M., S.G., and W.S. contributed to the study concept and design, data analysis/interpretation, and manuscript preparation. B.E. conducted the data analysis and interpretation and contributed to the manuscript preparation. All co-authors approved the final version of the manuscript.

References
1. Centers for Disease Control and Prevention. Varicella. In: Hamborsky J, Kroger A, Wolfe C, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington, DC: Public Health Foundation; 2015:1–24.
2. Marin M, Güris D, Chaves SS, et al; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1–40.
3. Centers for Disease Control and Prevention. Chickenpox vaccine saves lives and prevents serious illness. 2014. Available at: https://www.cdc.gov/about/24–7/savinglives/chickenpox/index.html. Accessed 8 July 2018.
4. Lopez AS, Zhang J, Marin M. Epidemiology of varicella during the 2-dose varicella vaccination program - United States, 2005–2014. MMWR Morb Mortal Wkly Rep 2016; 65:902–5.
5. Centers for Disease Control and Prevention. 2015 childhood varicella vaccination coverage report. 2016. Available at: https://www.cdc.gov/vaccines/imz-managers/coverage/childvaxview/data-reports/varicella/reports/2015.html. Accessed 8 July 2018.
6. Leung J, Marin M. Update on trends in varicella mortality during the varicella vaccine era—United States, 1990–2016. Hum Vaccin Immunother 2018; 14: 2460–3.
7. Vårtotav [prescribing information]. Kenilworth, NJ: Merck & Co, Inc.; 2018.
8. Galea SA, Sweet A, Beninger P, et al. The safety profile of varicella vaccine: a 10-year review. J Infect Dis 2008; 197(Suppl 2):S165–9.
9. Marin M, Marti M, Kambhampati A, et al. Global varicella vaccine effectiveness: a meta-analysis. Pediatrics 2016; 137:e20153741.
10. National Vaccine Information Center. The National Childhood Vaccination Injury Act of 1986. Available at: https://www.nvic.org/injury-compensation/orignhanlaw.aspx. Accessed 8 July 2018.
11. MedDRA. Medical Dictionary for Regulatory Activities. Available at: https://www.meddra.org. Accessed 13 April 2016.
12. Marin M, Willis ED, Marko A, Rasmussen SA, Bialek SR, Dana A. Closure of varicella-zoster virus-containing vaccines pregnancy registry - United States, 2013. MMWR Morb Mortal Wkly Rep 2014; 63:732–3.
13. ICH Expert Working Group. Post-approval safety data management: definitions and standards for expedited reporting E2D. 2003. Available at: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/ E2D_Guideline.pdf. Accessed 8 July 2018.
14. European Medicines Agency. ICH Topic E2A. Clinical safety data management: definitions and standards for expedited reporting; step 5. 1995. Available at: https://www.ema.europa.eu/documents/scientific-guideline/ich-topic-e2a-clinical-safety-data-management-definitions-and-standards-for-expedited-reporting-e2a-step-5-guideline.pdf. Accessed 8 July 2018.
15. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on the conduct of pharmacovigilance for vaccines for pre- and post-exposure prophylaxis against infectious diseases. 2009. Available at: https://www.ema.europa.eu/documents/scientific-guideline/ich-topic-e2a-clinical-safety-data-management-definitions-and-standards-for-expedited-reporting-e2a-step-5-guideline.pdf. Accessed 8 July 2018.
16. LaRussa P, Lungu O, Hardy I, et al. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella zoster virus isolates. J Virol 1992; 66:1016–20.
17. Centers for Disease Control and Prevention. Birth Defects and Genetic Diseases Branch 6-digit code for reportable congenital anomalies. 2007. Available at: https://www.cdc.gov/nchbddd/birthdefects/documents/MACDIDcode0807.pdf. Accessed 8 July 2018.
18. Cragan JD, Gilboa SM. Including prenatal diagnoses in birth defects monitoring: experience of the Metropolitan Atlanta Congenital Defects Program. Birth Defects Res A Clin Mol Teratol 2009; 85:20–9.
19. Centers for Disease Control and Prevention. Update on overall prevalence of major birth defects—Atlanta, GA, 1978–2005. MMWR Morb Mortal Wkly Rep 2008; 57:1–5.
20. European Medicines Agency. EMA guideline on good pharmacovigilance practices (GVP). Module VIII - post-authorisation safety studies (rev 3). 2017. Available at: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices. Accessed 25 October 2018.
21. Willis ED, Woodward M, Brown E, et al. Herpes zoster vaccine live: a 10-year review of post-marketing safety experience. Vaccine 2017; 35:7231–9.
22. European Medicines Agency. ICH topic E2E. Pharmacovigilance planning (PVP): step 5. 2005. Available at: https://www.ema.europa.eu/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-25.pdf. Accessed 8 July 2018.
23. Halsey NA, Edwards KM, Dekker CL, et al; Causality Working Group of the Clinical Immunization Safety Assessment network. Algorithm to assess causality after individual adverse events following immunizations. Vaccine 2012; 30:5791–8.
24. Cocchino S, Zanoni G, Orpi R, et al; Collaborative Group. A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy. Hum Vaccin Immunother 2016; 12:651–4.
25. Alicino C, Merlano C, Zappettini S, et al. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety. Hum Vaccin Immunother 2015; 11:91–4.
26. European Medicines Agency. EudraVigilance system overview. Important medical event list. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000166.jsp. Accessed 13 September 2017.
27. Leung J, Harpaz R. Impact of the maturing varicella vaccination program on varicella and related outcomes in the United States: 1994–2012. J Pediatr Infect Dis 2015; 5:395–402.
28. Duncan JR, Witkop CT, Webber BJ, Costello AA. Varicella seroepidemiology in United States Air Force recruits: a retrospective cohort study comparing immunogenicity of varicella vaccination and natural infection. Vaccine 2017; 35:2351–7.
29. Qi Q, Cavanagh MM, Le Saux S, et al. Defective T memory cell differentiation after varicella zoster vaccination in older individuals. PLoS Pathog 2016; 12:e1005892.
30. Papaloukas O, Giannouli G, Papaevangelou V. Successes and challenges in varicella vaccine. Ther Adv Vaccines 2014; 4:39–55.
31. Leung J, Broder KR, Marin M. Severe varicella in persons vaccinated with varicella vaccine (breakthrough varicella): a systematic literature review. Expert Rev Vaccines 2017; 16:391–400.
32. Arbetar AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986; 78:748–56.
33. Asano Y, Nakayama H, Yazaki T, et al. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics 1977; 59:3–7.
34. SIMPSON RE. Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). Lancet 1952; 2:549–54.
35. Horien C, Grose C. Neovirovaricella and the live attenuated varicella vaccine virus. Semin Pediatr Neurol 2012; 19:124–9.
36. Han JY, Hanson DC, Way SS. Herpes zoster and meningitis due to reactivation of varicella vaccine virus in an immunocompetent child. Pediatr Infect Dis J 2011; 30:266–8.
37. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2000; 19:916–23.